About Intersect ENT (NASDAQ:XENT)
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio7.37%
Quick Ratio6.89%
Price-To-Earnings
Trailing P/E Ratio-74.20
Forward P/E Ratio-68.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$96.30 million
Price / Sales12.86
Cash FlowN/A
Price / CashN/A
Book Value$3.98 per share
Price / Book10.44
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-16,360,000.00
Net Margins-16.99%
Return on Equity-14.40%
Return on Assets-12.71%
Miscellaneous
Employees327
Outstanding Shares29,810,000
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT (NASDAQ:XENT) announced its earnings results on Tuesday, February, 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.06. The medical equipment provider earned $29.53 million during the quarter, compared to analyst estimates of $29.45 million. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What price target have analysts set for XENT?
10 analysts have issued 12-month price objectives for Intersect ENT's shares. Their forecasts range from $25.00 to $41.00. On average, they expect Intersect ENT's share price to reach $33.4286 in the next twelve months. View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (4/7/2018)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Intersect following the earlier than expected FDA approval of Sinuva. Specifically, Intersect announced this morning that Sinuva was approved by the FDA with an indication for the treatment of nasal polyps. FDA approval came nearly a month ahead of management guidance and the FDA PDUFA date of January 7, 2018. We previously published a deep dive into the Sinuva product and market opportunity (link here). In sum, the clean approval removes FDA/regulatory overhang headed into YE/17 and positions the company with another meaningful growth driver in 2018 and beyond as Sinuva expands the market opportunity to include stand- alone treatment in the office setting. BUY." (12/11/2017)
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AngioDynamics (ANGO), AtriCure (ATRC), Cerus (CERS) and Anika Therapeutics (ANIK).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, Chief Exec. Officer, Pres and Director (Age 48)
- Ms. Jeryl L. Hilleman M.B.A, Chief Financial Officer (Age 60)
- Mr. Richard E. Kaufman, Chief Operating Officer (Age 56)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
- Ms. Gwen R. Carscadden, Chief People Officer (Age 57)
Has Intersect ENT been receiving favorable news coverage?
News coverage about XENT stock has been trending positive on Friday, according to Accern Sentiment. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intersect ENT earned a media sentiment score of 0.36 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
PRUDENTIAL FINANCIAL INC
(7.00%). Company insiders that own Intersect ENT stock include Amy Wolbeck, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $41.55.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $1.24 billion and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intersect ENT (NASDAQ:XENT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Intersect ENT in the last 12 months. Their average twelve-month price target is $33.4286, suggesting that the stock has a possible downside of 19.55%. The high price target for XENT is $41.00 and the low price target for XENT is $25.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.80 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $33.4286 | $33.4286 | $33.4286 | $27.1111 |
| Price Target Upside: | 19.55% downside | 9.28% downside | 3.17% upside | 12.54% downside |
Intersect ENT (NASDAQ:XENT) Consensus Price Target History
Intersect ENT (NASDAQ:XENT) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Intersect ENT (NASDAQ:XENT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intersect ENT (NASDAQ XENT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 84.49%
Intersect ENT (NASDAQ XENT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Lisa D Earnhardt | Insider | Sell | 15,000 | $39.59 | $593,850.00 | 499,683 |  |
| 4/3/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $37.66 | $483,290.78 | 36,265 | |
| 3/15/2018 | Lisa D Earnhardt | Insider | Sell | 15,000 | $38.32 | $574,800.00 | 499,683 | |
| 3/6/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $35.92 | $460,961.36 | 36,265 | |
| 2/15/2018 | Lisa D Earnhardt | Insider | Sell | 15,000 | $36.40 | $546,000.00 | 499,683 | |
| 2/6/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $35.80 | $459,421.40 | 25,765 | |
| 2/1/2018 | Richard E Kaufman | COO | Sell | 958 | $37.21 | $35,647.18 | 87,512 | |
| 1/18/2018 | Lisa D Earnhardt | Insider | Sell | 11,166 | $33.47 | $373,726.02 | 495,849 | |
| 1/17/2018 | Richard E Kaufman | COO | Sell | 50,000 | $33.33 | $1,666,500.00 | 107,470 | |
| 1/12/2018 | Gwen R Carscadden | Insider | Sell | 10,000 | $34.35 | $343,500.00 | 13,856 | |
| 1/11/2018 | Jeryl L Hilleman | CFO | Sell | 12,835 | $33.81 | $433,951.35 | 25,767 | |
| 12/15/2017 | Lisa D Earnhardt | Insider | Sell | 10,685 | $31.87 | $340,530.95 | 487,868 | |
| 12/11/2017 | David Aaron Lehman | General Counsel | Sell | 36,000 | $32.75 | $1,179,000.00 | 45,000 | |
| 12/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $30.06 | $385,759.98 | 27,833 | |
| 11/20/2017 | Frederic H Moll | Director | Sell | 14,200 | $28.76 | $408,392.00 | 247,124 | |
| 11/16/2017 | Frederic H Moll | Director | Sell | 6,700 | $28.77 | $192,759.00 | 247,124 | |
| 11/10/2017 | Frederic H Moll | Director | Sell | 800 | $29.00 | $23,200.00 | 253,824 | |
| 11/6/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $27.78 | $356,500.74 | 27,833 | |
| 10/16/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $28.37 | $567,400.00 | | |
| 10/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $29.96 | $384,476.68 | | |
| 9/25/2017 | Richard E Kaufman | COO | Sell | 13,639 | $28.97 | $395,121.83 | 133,757 | |
| 9/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $30.19 | $603,800.00 | 525,868 | |
| 9/5/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $31.05 | $398,464.65 | 27,833 | |
| 8/28/2017 | Richard E Kaufman | COO | Sell | 22,425 | $30.22 | $677,683.50 | 149,821 | |
| 8/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $30.79 | $615,800.00 | 525,868 | |
| 8/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $29.00 | $372,157.00 | 27,833 | |
| 7/25/2017 | Richard E Kaufman | COO | Sell | 12,500 | $28.25 | $353,125.00 | 169,821 | |
| 7/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $29.03 | $580,600.00 | 580,868 | |
| 7/10/2017 | Jeryl L Hilleman | CFO | Sell | 12,835 | $27.18 | $348,855.30 | 27,835 | |
| 6/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $26.10 | $522,000.00 | 583,493 | |
| 5/22/2017 | Richard E Kaufman | COO | Sell | 20,000 | $22.87 | $457,400.00 | 182,321 | |
| 5/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $22.98 | $459,600.00 | 600,868 | |
| 4/20/2017 | Richard E Kaufman | COO | Sell | 1,250 | $17.25 | $21,562.50 | 202,321 | |
| 4/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $16.06 | $321,200.00 | 610,868 | |
| 3/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $15.02 | $300,400.00 | 620,868 | |
| 10/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.58 | $59,737.74 | 194,571 | |
| 10/17/2016 | Lisa D Earnhardt | Insider | Sell | 400 | $18.00 | $7,200.00 | 557,268 | |
| 9/7/2016 | Amy Wolbeck | VP | Sell | 28,664 | $15.83 | $453,751.12 | 18,076 | |
| 9/6/2016 | James Stambaugh | VP | Sell | 4,000 | $16.00 | $64,000.00 | 23,700 | |
| 8/3/2016 | James Stambaugh | VP | Sell | 3,977 | $17.00 | $67,609.00 | 27,977 | |
| 7/18/2016 | James Stambaugh | VP | Sell | 5,000 | $15.33 | $76,650.00 | 29,000 | |
| 6/13/2016 | James Stambaugh | VP | Sell | 500 | $14.38 | $7,190.00 | 24,000 | |
| 5/16/2016 | Kieran Gallahue | Director | Buy | 8,000 | $12.64 | $101,120.00 | 8,000 | |
| 4/27/2016 | Amy Wolbeck | VP | Sell | 2,000 | $20.01 | $40,020.00 | 7,700 | |
| 4/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.86 | $67,952.58 | 198,174 | |
| 4/18/2016 | Lisa D Earnhardt | CEO | Sell | 28,500 | $18.69 | $532,665.00 | 581,368 | |
| 3/21/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.51 | $59,485.53 | 201,777 | |
| 3/15/2016 | Lisa D Earnhardt | CEO | Sell | 9,000 | $18.01 | $162,090.00 | 561,368 | |
| 3/14/2016 | Frederic H Moll | Director | Sell | 1,299 | $18.53 | $24,070.47 | 252,078 | |
| 3/8/2016 | Frederic H Moll | Director | Sell | 601 | $18.56 | $11,154.56 | 253,377 | |
| 2/22/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.65 | $67,195.95 | 205,380 | |
| 1/21/2016 | Richard E. Kaufman | COO | Sell | 7,206 | $17.93 | $129,203.58 | 208,983 | |
| 1/15/2016 | Lisa D. Earnhardt | CEO | Sell | 12,500 | $19.26 | $240,750.00 | 570,368 | |
| 12/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,820 | $19.85 | $135,377.00 | 574,868 | |
| 11/16/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.00 | $122,724.00 | 581,688 | |
| 10/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.72 | $127,632.96 | 588,506 | |
| 9/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $25.99 | $177,199.82 | 595,324 | |
| 9/11/2015 | Frederic H Moll | Director | Sell | 10,000 | $25.21 | $252,100.00 | 282,428 | |
| 8/17/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $28.51 | $194,381.18 | | |
| 7/20/2015 | James Stambaugh | VP | Sell | 12,000 | $30.52 | $366,240.00 | | |
| 7/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.62 | $572,199.16 | | |
| 6/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.30 | $566,017.40 | | |
| 5/8/2015 | James Stambaugh | VP | Sell | 2,785 | $23.87 | $66,477.95 | | |
| 4/13/2015 | Amy Wolbeck | VP | Sell | 16,000 | $26.25 | $420,000.00 | | |
| 4/1/2015 | James Stambaugh | VP | Sell | 8,343 | $25.50 | $212,746.50 | | |
| 3/16/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $23.56 | $455,132.08 | | |
| 3/11/2015 | Amy Wolbeck | VP | Sell | 8,000 | $23.06 | $184,480.00 | | |
| 3/9/2015 | James Stambaugh | VP | Sell | 8,343 | $23.02 | $192,055.86 | | |
| 2/17/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $22.69 | $438,325.42 | | |
| 2/12/2015 | Amy Wolbeck | VP | Sell | 8,000 | $22.12 | $176,960.00 | | |
| 2/2/2015 | James Stambaugh | VP | Sell | 8,343 | $20.98 | $175,036.14 | | |
| 1/26/2015 | Robert H Binney Jr | VP | Sell | 6,300 | $21.18 | $133,434.00 | | |
| 9/11/2014 | Cynthia L Lucchese | Director | Buy | 5,000 | $17.11 | $85,550.00 | | |
(Data available from 1/1/2013 forward)
Intersect ENT (NASDAQ XENT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Intersect ENT (XENT) Insider Sells $593,850.00 in Stock
www.americanbankingnews.com - April 17 at 7:13 PM |
 | Intersect ENT to Present at Deutsche Bank and Bank of America Merrill Lynch Conferences
finance.yahoo.com - April 17 at 5:05 PM |
| Intersect ENT (XENT) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 17 at 9:57 AM |
| Intersect ENT to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 16 at 4:35 PM |
| $23.68 Million in Sales Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - April 16 at 5:03 AM |
| Intersect ENT (XENT) Given a $31.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - April 14 at 9:37 AM |
| Intersect ENT (XENT) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 14 at 1:09 AM |
| Intersect ENT (XENT) Upgraded by TheStreet to C-
www.americanbankingnews.com - April 13 at 7:51 PM |
 | Commit To Buy Intersect ENT At $30, Earn 9.7% Annualized Using Options
www.nasdaq.com - April 13 at 4:40 PM |
| Zacks Investment Research Reiterates "Hold" Rating for Intersect ENT (XENT)
www.americanbankingnews.com - April 7 at 4:27 PM |
| Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock
www.americanbankingnews.com - April 4 at 10:56 PM |
| Intersect ENT (XENT) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 4 at 12:55 PM |
 | Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal ...
www.businesswire.com - April 3 at 9:31 AM |
| Intersect ENT (XENT) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM |
| Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
finance.yahoo.com - April 2 at 9:43 AM |
| Intersect ENT's (XENT) Hold Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 1 at 4:16 PM |
| Intersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 31 at 3:38 AM |
| $23.68 Million in Sales Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - March 30 at 4:19 AM |
| Zacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 28 at 3:13 AM |
| Reviewing Reshape Lifesciences (RSLS) & Intersect ENT (XENT)
www.americanbankingnews.com - March 25 at 9:04 PM |
| Intersect ENT (XENT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 25 at 2:00 PM |
| Intersect ENT (XENT) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 24 at 11:46 PM |
| Intersect ENT (XENT) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 22 at 9:21 AM |
| Intersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 15,000 Shares
www.americanbankingnews.com - March 16 at 7:34 PM |
| Zacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 10 at 7:14 PM |
| Intersect ENT Inc (XENT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 3:28 AM |
| Q1 2018 Earnings Forecast for Intersect ENT Inc (XENT) Issued By Leerink Swann
www.americanbankingnews.com - March 5 at 1:10 AM |
| Equities Analysts Issue Forecasts for Intersect ENT Inc's Q1 2018 Earnings (XENT)
www.americanbankingnews.com - March 5 at 1:10 AM |
| Bogle Investment Management L P DE Sells 55,776 Shares of Intersect ENT Inc (XENT)
www.americanbankingnews.com - March 4 at 4:58 AM |
| William Blair Comments on Intersect ENT Inc's Q1 2019 Earnings (XENT)
www.americanbankingnews.com - March 2 at 3:01 PM |
| Intersect ENT (XENT) Receives Buy Rating from Guggenheim
www.americanbankingnews.com - March 1 at 6:45 PM |
| EAM Investors LLC Has $2.17 Million Position in Intersect ENT Inc (XENT)
www.americanbankingnews.com - March 1 at 12:13 PM |
| Intersect ENT Inc (XENT) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 1 at 8:59 AM |
| Intersect ENT (XENT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 28 at 3:45 PM |
| Intersect ENT (XENT) Posts Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - February 28 at 10:47 AM |
| Intersect ENT Inc’s (NASDAQ:XENT) Path To Profitability
finance.yahoo.com - February 27 at 5:12 PM |
| Intersect ENT Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 27 at 5:12 PM |
| Intersect ENT (XENT) versus CONMED (CNMD) Financial Review
www.americanbankingnews.com - February 27 at 11:42 AM |
| Intersect ENT Inc (XENT) Expected to Post Quarterly Sales of $29.45 Million
www.americanbankingnews.com - February 24 at 10:56 AM |
| Comparing Intersect ENT (XENT) & Nevro (NVRO)
www.americanbankingnews.com - February 24 at 8:06 AM |
| Intersect ENT (XENT) and Alliqua Biomedical (ALQA) Critical Review
www.americanbankingnews.com - February 23 at 2:20 PM |
| Brokerages Expect Intersect ENT Inc (XENT) to Post -$0.17 EPS
www.americanbankingnews.com - February 22 at 3:14 AM |
| Intersect ENT (XENT) to Release Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM |
| Lisa D. Earnhardt Sells 15,000 Shares of Intersect ENT Inc (XENT) Stock
www.americanbankingnews.com - February 16 at 9:44 PM |
| Intersect ENT Inc (XENT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 9 at 3:48 AM |
| Intersect ENT to Report Fourth Quarter and Year 2017 Financial Results
finance.yahoo.com - February 8 at 4:15 PM |
| Intersect ENT Inc (XENT) CFO Jeryl L. Hilleman Sells 12,833 Shares
www.americanbankingnews.com - February 8 at 12:30 AM |
| Insider Selling: Intersect ENT Inc (XENT) COO Sells 958 Shares of Stock
www.americanbankingnews.com - February 5 at 7:16 PM |
| -$0.17 EPS Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - February 5 at 3:12 AM |
| Intersect ENT (XENT) Upgraded at BidaskClub
www.americanbankingnews.com - January 27 at 8:42 PM |
Intersect ENT (NASDAQ:XENT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intersect ENT (NASDAQ:XENT) Income Statement, Balance Sheet and Cash Flow Statement
Intersect ENT (NASDAQ XENT) Stock Chart for Friday, April, 20, 2018
Loading chart…
